Additional file 1 of A gold nanoparticle/peptide vaccine designed to induce SARS-CoV-2-specific CD8 T cells: a double-blind, randomized, phase 1 study in Switzerland

Supplementary Material 1. Appendix A: Inclusion and exclusion criteria. Appendix B: Candidate vaccine. Appendix C: Assessment of adverse events. Appendix D: Immunological analysis methods. Table A1. Covid19 peptides. Table A2. Dextramers. Table A3. List of markers for flow cytometry. Figure A1. Gating strategy, AIM analysis. Figure A2. Gating strategy, dextramer analysis. Appendix E: Results. Table A4: Safety profile. Table A5. Covid19-specific responders in AIM, differential cut-off, ITT analysis. Table A6. HLA Typing. Figure A3. Change from baseline of anti-Covid19 serology. Figure A4. Change from baseline of PepGNP-Covid19-elicited specific CD8 T cells using AIM. Figure A5. Vehicle-GNP-specific T cell response according to GNP dose. Figure A6. HLA-A and HLA-B allele results. Figure A7. C-dextr+CD8+ responses: correlation between AUC and baseline. Figure A8. Covid19-dextramer+ CD8+ memory subsets (PP analysis). Figure A9. All memory C-dextr+CD8+. Figure A10. CXCR3+C-dextr+CD8+ memory subsets. Figure A11. Frequency and profile of Covid19-specific CD8+ T cells in infected and uninfected participants at baseline. Figure A12. Dextramer controls.